Targeting the Metastatic Tumor Microenvironment to Limit Cancer Progression

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.

Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.

Recent Videos
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.

Data Show Disease Control With Inavolisib in Advanced PIK3CA+ Solid Tumors

Ryan Scott
October 7th 2024
Article

Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer

Jax DiEugenio
October 6th 2024
Article

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

Russ Conroy
October 4th 2024
Article

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM

Jordyn Sava
October 4th 2024
Article

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.